Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Humble yeast sheds light on promising anti-cancer drug

19.10.2005


Research from the Journal of the National Cancer Institute



The humble yeast has revealed the molecular workings of an anti-cancer drug that stops the growth and spread of tumours in humans by starving their blood supply.

Until now, University of New South Wales scientists who developed the drug (GSAO) knew that it was lethal against endothelial cells but not why it had no direct impact on tumours themselves.


The new study reveals that endothelial cells lack the "transport protein" that tumours use to eject foreign molecules that invade their cell structure.

Endothelial cells are the building blocks of blood vessels. Cancer cells rely on blood vessel growth, known as angiogenesis, to grow and spread to other parts of the body.

"It’s very sexy science," says one the research authors, Professor Philip Hogg, a biochemist with the UNSW Centre for Vascular Research and the Children’s Cancer Institute Australia. "We now understand how an anti-cancer drug works in humans thanks to genetic studies using the humble yeast cell."

Published in today’s edition of the prestigious Journal of the National Cancer Institute, the study reveals how researchers "genetically fingerprinted" the transport protein by using genetically modified (mutant) yeast cells. The researchers used 4800 yeast mutants that represent every non-essential gene in the genome.

"The mutant yeast cells that were vulnerable to the drug lacked the protein that enables them to eject the drug across their cell membrane," says Professor Ian Dawes, a study co-author from the UNSW Ramaciotti Centre for Gene Function Analysis.

"Yeast cells that lacked the protein died, while those that had the protein didn’t," says Dawes. "That told us there was a specific gene encoding a protein that’s vital for a cell to protect itself against GSAO."

Once the researchers knew this they looked for and found a corresponding protein in humans, known as a multi-drug resistance associated protein (MRP).

"The presence of these transport proteins in tumours is one of the reasons that anti-cancer drugs such as chemotherapy medicines fail against cancer," says Professor Hogg.

"The reason that GSAO is effective is that it targets tumours indirectly by attacking the endothelial cells that lack this transport protein. So GSAO is lethal against tumours because it chokes the blood supply they rely on to grow and spread."

The amazing thing is that we’ve used the humble yeast, which is a less sophisticated cell than a human cell, to reveal the molecular secrets of the drug and how it works in humans.

The GSAO story

GSAO (glutathionarsenoxide) is an angiogenesis inhibitor drug that "starves" tumour cells by stopping them from making blood vessels -- known as angiogenesis - that tumours rely on to grow and spread. Professor Philip Hogg and Dr Neil Donoghue from the University of New South Wales invented GSAO in 1999.

Because all solid tumours of children and adults, such as cancer of the breast, prostate, colon, lung and brain rely on angiogenesis, a single anti-angiogenic drug should be effective against all tumour types. This is in contrast to chemotherapy drugs and radiotherapy that are often effective only against certain tumour types. Also, because GSAO is not a conventional "cytotoxic" drug that poisons cancer cells, it does not cause unpleasant side effects such as nausea and hair loss.

Small blood vessels consist primarily of endothelial cells that line their interior. They are genetically stable, in contrast to tumour cells that are inherently unstable. Most tumour cells have a propensity for mutation and genetic diversity, and are therefore likely to produce drug resistant cells. The genetic stability of endothelial cells suggests that anti-angiogenic drugs that target the stimulated endothelial cells in tumours will be less prone to resistance than the chemotherapeutic agents that target the tumour cells.

While GSAO would not "cure" people of the cancer, it should stop most types of tumours in their tracks. This means that the focus of cancer treatment and research could move away from curing the disease to one of managing it on a life-long basis, such as diabetes.

GSAO will be first tested in cancer patients in 2006.

Prof. Philip Hogg | EurekAlert!
Further information:
http://www.unsw.edu.au

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>